is predicted to increase the exposure to gefitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Crizotinib potentially decreases the exposure to glecaprevir.
▶ Grapefruit juice is predicted to increase the exposure to
crizotinib. Avoid.oTheoretical
▶ Crizotinib is predicted to increase the concentration of
guanfacine. Adjust guanfacine dose, p. 352.oTheoretical
▶ HIV-protease inhibitors are predicted to moderately increase
the exposure to crizotinib. Avoid.oStudy → Also see
▶ Crizotinib is predicted to increase the exposure to ibrutinib.
Adjust ibrutinib dose with moderate inhibitors of CYP3A4,
p. 983.rStudy → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to moderately increase the exposure to
crizotinib. Avoid.oStudy → Also see TABLE 15 p. 1378
▶ Crizotinib is predicted to increase the exposure to ivabradine.
Adjust ivabradine dose, p. 211.rTheoretical → Also see
▶ Crizotinib is predicted to increase the exposure to ivacaftor.
Adjust ivacaftor p. 293 or tezacaftor with ivacaftor p. 295 dose
with moderate inhibitors of CYP3A4.rStudy
is predicted to increase the exposure to lapatinib.
Study → Also see TABLE 9 p. 1377
▶ Crizotinib is predicted to increase the exposure to lomitapide.
▶ Crizotinib is predicted to increase the exposure to lurasidone.
Adjust lurasidone dose, p. 398.oStudy
▶ Macrolides (clarithromycin) are predicted to moderately
increase the exposure to crizotinib. Avoid.oStudy →
▶ Crizotinib is predicted to increase the exposure to midazolam.
Monitor side effects and adjust dose.rStudy
is predicted to increase the exposure to midostaurin.
▶ Mitotane is predicted to markedly decrease the exposure to
crizotinib. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Crizotinib is predicted to increase the exposure to naloxegol.
▶ Crizotinib is predicted to increase the exposure to olaparib.
Avoid moderate inhibitors of CYP3A4 or adjust olaparib dose,
p. 1005.oTheoretical → Also see TABLE 15 p. 1378
▶ Crizotinib is predicted to increase the exposure to opioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
adjust dose.oStudy → Also see TABLE 6 p. 1376
▶ Crizotinib is predicted to increase the exposure to opioids
(methadone, sufentanil).oTheoretical → Also see TABLE 6
p. 1376 → Also see TABLE 9 p. 1377
▶ Crizotinib is predicted to increase the exposure to oxybutynin.
is predicted to increase the exposure to pazopanib.
Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9
▶ Crizotinib is predicted to increase the risk of bleeding events
when given with phenindione.rTheoretical
▶ Crizotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil
▶ Crizotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (sildenafil). Monitor or
adjust sildenafil dose with moderate inhibitors of CYP3A4,
p. 813.oStudy → Also see TABLE 9 p. 1377
▶ Crizotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (tadalafil).rTheoretical
▶ Crizotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose.
Theoretical → Also see TABLE 9 p. 1377
▶ Crizotinib potentially decreases the exposure to pibrentasvir.
▶ Crizotinib is predicted to increase the exposure to pimozide.
Avoid.rTheoretical → Also see TABLE 9 p. 1377
▶ Pitolisant is predicted to decrease the exposure to crizotinib.
▶ Crizotinib is predicted to increase the exposure to quetiapine.
is predicted to increase the exposure to ranolazine.
Study → Also see TABLE 9 p. 1377
is predicted to increase the exposure to ribociclib.
Study → Also see TABLE 9 p. 1377
▶ Rifampicin is predicted to markedly decrease the exposure to
is predicted to increase the exposure to ruxolitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Crizotinib is predicted to increase the exposure to saxagliptin.
▶ Crizotinib increases the concentration of sirolimus. Monitor
▶ Crizotinib is predicted to increase the exposure to SSRIs
(dapoxetine). Adjust dapoxetine dose with moderate inhibitors
of CYP3A4, p. 821.oTheoretical
▶ St John’s Wort is predicted to decrease the exposure to
crizotinib. Avoid.rTheoretical
▶ Crizotinib is predicted to increase the exposure to statins
(atorvastatin). Monitor and adjust dose.rStudy
▶ Crizotinib is predicted to increase the exposure to statins
(simvastatin). Use with caution and adjust simvastatin dose,
is predicted to increase the exposure to sunitinib.
Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9
▶ Crizotinib is predicted to increase the concentration of
1438 Crizotinib — Crizotinib BNF 78
▶ Crizotinib is predicted to increase the exposure to taxanes
(cabazitaxel).oTheoretical → Also see TABLE 15 p. 1378
▶ Crizotinib is predicted to increase the concentration of
temsirolimus.oTheoretical → Also see TABLE 15 p. 1378
▶ Crizotinib is predicted to increase the exposure to tezacaftor.
Adjust tezacaftor with ivacaftor p. 295 dose with moderate
▶ Crizotinib given with a potent CYP2C19 inhibitor is predicted
to increase the exposure to tofacitinib. Adjust tofacitinib dose,
▶ Crizotinib is predicted to increase the exposure to tolterodine.
nTheoretical → Also see TABLE 9 p. 1377
▶ Crizotinib is predicted to increase the exposure to tolvaptan.
Manufacturer advises caution or adjust tolvaptan dose with
moderate inhibitors of CYP3A4, p. 669.oStudy
is predicted to increase the exposure to trazodone.
▶ Crizotinib is predicted to increase the exposure to ulipristal.
Avoid if used for uterine fibroids.oStudy
▶ Crizotinib is predicted to increase the exposure to venetoclax.
Avoid or adjust dose—consult product literature.rStudy
▶ Crizotinib is predicted to increase the exposure to vinca
alkaloids.rTheoretical → Also see TABLE 15 p. 1378 → Also see
▶ Crizotinib is predicted to increase the exposure to zopiclone.
Cyclizine → see antihistamines, sedating
Cyclopentolate → see TABLE 10 p. 1377 (antimuscarinics)
Cyclophosphamide → see alkylating agents
▶ Cycloserine increases the risk of CNS toxicity when given with
isoniazid. Monitor and adjust dose.oStudy
Cyproheptadine → see antihistamines, sedating
Cytarabine → see TABLE 15 p. 1378 (myelosuppression)
decreases the concentration of flucytosine. Avoid.
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
cytarabine. Public Health England advises avoid (refer to
Dabigatran → see TABLE 3 p. 1375 (anticoagulant effects)
▶ Antiarrhythmics (amiodarone) increase the exposure to
dabigatran. Adjust dabigatran dose, p. 136.oStudy
▶ Antiarrhythmics (dronedarone) slightly increase the exposure to
▶ Antiepileptics (carbamazepine) are predicted to decrease the
exposure to dabigatran. Avoid.rStudy
▶ Antiepileptics (phenytoin) are predicted to decrease the
exposure to dabigatran. Avoid.rTheoretical
▶ Antifungals, azoles (isavuconazole) are predicted to increase the
increase the exposure to dabigatran. Avoid.rStudy
▶ Apalutamide is predicted to decrease the exposure to
▶ Brigatinib potentially increases the concentration of
▶ Calcium channel blockers (verapamil) increase the exposure to
dabigatran. Adjust dabigatran dose, p. 136.rStudy
is predicted to increase the exposure to dabigatran.
▶ Ciclosporin is predicted to increase the exposure to dabigatran.
▶ Cobicistat is predicted to increase the exposure to dabigatran.
▶ Elbasvir is predicted to increase the concentration of
▶ Eliglustat is predicted to increase the exposure to dabigatran.
▶ Glecaprevir (with pibrentasvir) increases the exposure to
▶ HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are
predicted to increase the exposure to
is predicted to increase the exposure to dabigatran.
is predicted to increase the exposure to dabigatran.
▶ Letermovir is predicted to decrease the concentration of
dabigatran. Avoid.rTheoretical
▶ Macrolides are predicted to increase the exposure to
▶ Mirabegron is predicted to increase the exposure to
▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to
increase the exposure to dabigatran.rStudy
▶ Pibrentasvir (with glecaprevir) increases the exposure to
▶ Pitolisant is predicted to decrease the exposure to dabigatran.
is predicted to increase the exposure to dabigatran.
▶ Rifampicin is predicted to decrease the exposure to dabigatran.
is predicted to increase the exposure to dabigatran.
▶ St John’s Wort is predicted to decrease the exposure to
▶ Tacrolimus is predicted to increase the exposure to dabigatran.
increases the exposure to dabigatran. Avoid.
▶ Vemurafenib increases the exposure to dabigatran. Use with
caution and adjust dose.rTheoretical
▶ Venetoclax is predicted to increase the exposure to dabigatran.
▶ Voxilaprevir (with sofosbuvir and velpatasvir) increases the
concentration of dabigatran. Avoid.rStudy
Dabrafenib → see TABLE 15 p. 1378 (myelosuppression)
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to dabrafenib. Avoid.oTheoretical
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to dabrafenib. Use with
▶ Clopidogrel is predicted to increase the exposure to
▶ Cobicistat is predicted to increase the exposure to dabrafenib.
Use with caution or avoid.oStudy
▶ Dabrafenib is predicted to decrease the anticoagulant effect of
▶ Dabrafenib is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Enzalutamide is predicted to decrease the exposure to
dabrafenib. Avoid.oTheoretical
▶ Fibrates (gemfibrozil) are predicted to increase the exposure to
▶ HIV-protease inhibitors are predicted to increase the exposure
to dabrafenib. Use with caution or avoid.oStudy
▶ Idelalisib is predicted to increase the exposure to dabrafenib.
Use with caution or avoid.oStudy → Also see TABLE 15
▶ Macrolides (clarithromycin) are predicted to increase the
▶ Mitotane is predicted to decrease the exposure to dabrafenib.
Avoid.oTheoretical → Also see TABLE 15 p. 1378
▶ Rifampicin is predicted to decrease the exposure to dabrafenib.
Dacarbazine → see alkylating agents
Dactinomycin → see TABLE 1 p. 1375 (hepatotoxicity), TABLE 15 p. 1378
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
dactinomycin. Public Health England advises avoid (refer to
BNF 78 Crizotinib — Dactinomycin 1439
▶ Dairy products are predicted to decrease the absorption of
eltrombopag. Eltrombopag should be taken 2 hours before or
4 hours after dairy products.rTheoretical
▶ Dairy products decrease the exposure to tetracyclines
(demeclocycline, oxytetracycline, tetracycline)
Dalteparin → see low molecular-weight heparins
Danaparoid → see TABLE 3 p. 1375 (anticoagulant effects)
▶ Ranibizumab is predicted to increase the risk of bleeding
events when given with danaparoid.rTheoretical
▶ Danazol moderately increases the concentration of
(carbamazepine). Monitor and adjust dose.r
increases the concentration of ciclosporin.r
▶ Danazol potentially increases the anticoagulant effect of
▶ Danazol is predicted to increase the risk of rhabdomyolysis
when given with statins (atorvastatin).rTheoretical
▶ Danazol increases the risk of rhabdomyolysis when given with
statins (simvastatin). Avoid.rAnecdotal
potentially increases the concentration of tacrolimus.
Dantrolene → see TABLE 1 p. 1375 (hepatotoxicity)
▶ Intravenous dantrolene potentially increases the risk of acute
hyperkalaemia and cardiovascular collapse when given with
(diltiazem, verapamil). Avoid.r
Dapagliflozin → see TABLE 14 p. 1378 (antidiabetic drugs), TABLE 8
▶ Aminosalicylic acid is predicted to increase the risk of
methaemoglobinaemia when given with
▶ Dapsone is predicted to increase the risk of
methaemoglobinaemia when given with topical anaesthetics,
local (prilocaine). Use with caution or avoid.rTheoretical
▶ Antiepileptics (fosphenytoin, phenobarbital, phenytoin,
primidone) are predicted to increase the risk of
methaemoglobinaemia when given with dapsone.r
▶ Antimalarials (chloroquine, primaquine) are predicted to
increase the risk of methaemoglobinaemia when given with
▶ Nitrates are predicted to increase the risk of
methaemoglobinaemia when given with
▶ Nitrofurantoin is predicted to increase the risk of
methaemoglobinaemia when given with
▶ Paracetamol is predicted to increase the risk of
methaemoglobinaemia when given with dapsone.r
▶ Rifabutin decreases the exposure to dapsone.oStudy
▶ Rifampicin decreases the exposure to dapsone.oStudy
▶ Sodium nitroprusside is predicted to increase the risk of
methaemoglobinaemia when given with
▶ Sulfonamides are predicted to increase the risk of
methaemoglobinaemia when given with dapsone.r
▶ Dapsone increases the exposure to trimethoprim and
trimethoprim increases the exposure to dapsone.rStudy
▶ Aspirin (high-dose) increases the risk of renal impairment
when given with daptomycin.oTheoretical
▶ Ciclosporin is predicted to increase the risk of rhabdomyolysis
when given with daptomycin.rTheoretical
▶ Fibrates are predicted to increase the risk of rhabdomyolysis
when given with daptomycin.rTheoretical
▶ NSAIDs increase the risk of renal impairment when given with
▶ Statins are predicted to increase the risk of rhabdomyolysis
when given with daptomycin.rTheoretical
Daratumumab → see monoclonal antibodies
Darbepoetin alfa → see TABLE 5 p. 1375 (thromboembolism), TABLE 16
p. 1379 (increased serum potassium)
Darifenacin → see TABLE 10 p. 1377 (antimuscarinics)
▶ Antiarrhythmics (dronedarone) are predicted to slightly
increase the exposure to darifenacin.oStudy
▶ Darifenacin is predicted to increase the concentration of
antiarrhythmics (flecainide).oTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
Comments
Post a Comment
اكتب تعليق حول الموضوع